The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago.
Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.

The USD 3.6 billion (by 2030) financial opportunity within the Target Protein Degradation Market has been analyzed across the following segments:

Type of payment of licensing agreements

• Upfront payments
• Milestone payments
Type of protein degrader
• Degronimids
• PROTACs
• SARDs / SERDs
• Specific BET and DUB inhibitors
• Other protein degraders

Therapeutic area

• Neurodegenerative disorders
• Oncological disorders
• Other therapeutic areas

Route of administration

• Oral
• Intravenous
• Other routes

Key geographical region

• North America
• Europe
• Asia-Pacific

The Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 report features the following companies, which we identified to be key players in this domain:

Key Players

• Arvinas
• Captor Therapeutics
• Celgene
• Genetech
• Kymera Therapeutics
• Mission Therapeutics
• Progenra
• Radius Health
• Sanofi Genzyme
• Zenopharm

The ‘Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics (2nd Edition), 2021-2030: Distribution by Type of Protein degrader (degronimids, PROTACs, SARDs / SERDs, and specific BET and DUB inhibitors, and other inhibitors), Therapeutic Area (Neurological Disorders, Oncological Disorders, and Other Therapeutic Areas), Route of administration (Oral, Intravenous and Others), Key Contributing Technologies and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, Middle East, and North Africa, and Rest of the World)’ report features an extensive study of the current and future potential of protein degraders, offering an informed opinion on the likely adoption of these therapeutics and affiliated technologies, over the next decade. The focus of this study is on specially designed small-molecule degraders, including degronimids, endosome targeting chimeras (ENDTACs), epichaperome inhibitors, hydrophobic tags, immuno-modulatory imide drugs (IMiDs), lysosome targeting chimeras (LYTACs), molecular glues, photochemically targeting chimeras (PHOTACs), proteolysis targeting chimeras (PROTACs), protein homeostatic modulators, selective androgen receptor degraders (SARDs), selective estrogen receptor degraders (SERDs), specific and non-genetic IAP-dependent protein erasers (SNIPERs), and specific bromodomain and extra-terminal motif (BET) inhibitors and deubiquitinase (DUB) inhibitors. In addition, the report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. Amongst other elements, the report includes:

A detailed review of the current market landscape of targeted protein degradation-based therapeutics, including information on the type of protein degrader (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase of development (clinical, preclinical, and discovery stage) of product candidates, target indication(s), key therapeutic area(s), type of biological target(s), associated ubiquitin ligase(s) (if available), target signaling pathway (if available), mechanism of action (if available), type of therapy (monotherapy and combination therapy), route of administration (oral, intravenous and others). In addition, it presents a list of drug/therapy developer(s) (such as year of establishment, company size, and location of headquarters), clinical study sponsor(s), and collaborator(s).
An overview of the overall landscape of target protein degradation enabling technologies, featuring an analysis based on the type of degrader. In addition, it presents a list of targeted protein degradation enabling technology developers and analysis based on various parameters, such as year of establishment, company size, and location of headquarters.
Detailed profiles of prominent players engaged in the development of targeted protein degraders (shortlisted on the basis of phase of development of pipeline products). Each profile features a brief overview of the company, its financial information (if available), a detailed description of their respective lead drug candidates, and recent developments, and an informed future outlook. Additionally, each drug profile features information on the type of drug, current status of development, route of administration, target indications, and a brief summary of its developmental history.
Tabulated profiles of leading industry players (shortlisted on the basis of the number of candidates in the development pipeline). Each profile includes details on the innovator company (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along information on respective drug candidates.
An in-depth analysis of completed, ongoing, and planned studies of various targeted protein degraders, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of protein degrader, phase of development, study design, leading industry and non-industry players (in terms of a number of trials conducted), trial focus, target therapeutic area, key indications, and clinical endpoints.
A detailed analysis of grants that have been awarded to various research institutes for targeted protein degradation projects, in the period between 2017 and 2020, on the basis of important parameters, such as year of the award, the amount awarded, administering institute center, support period, funding mechanism, type of grant application, the purpose of the grant award, activity code, emerging focus areas of the grants, study section, popular NIH departments, study section, and type of recipient organization, highlighting popular recipient organizations, popular program officers and regional distribution of recipient organizations.

Table of Contents

1. Preface
2. Executive Summary
3. Introduction
4. Current Market Landscape
5. Company Profiles
6. Clinical Trial Analysis
7. KOL Analysis
8. Publication Analysis
9. Funding and Investment Analysis
10. Partnerships and Collaborations
11. Market Sizing and Opportunity Analysis
12. Executive Insights
13. Concluding Remarks
14. Appendix 1: Tabulated Data
15. Appendix 2: List of Companies and Organizations

About Roots Analysis

Roots Analysis is one of the fastest-growing market research companies, sharing fresh and independent perspectives in the biopharmaceutical industry. The in-depth research, analysis, and insights are driven by an experienced leadership team that has gained many years of significant experience in this sector.

Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]

Also, Visit Our Latest Publication:
Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market
CAR-T Cell Therapies Market
Patient Recruitment and Retention Services Market
mRNA Therapeutics and Vaccines Market
T-Cell (CAR-T, TCR, and TIL) Therapies Market